The gut microbiota market size has grown rapidly in recent years. It will grow from $0.65 billion in 2025 to $0.77 billion in 2026 at a compound annual growth rate (CAGR) of 18%. The growth in the historic period can be attributed to improved understanding of gut health and immunity, expansion of dietary supplement consumption, growth of functional food markets, increased academic research on microbiota, rising consumer awareness of digestive health.
The gut microbiota market size is expected to see rapid growth in the next few years. It will grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to increasing development of microbiome-targeted therapeutics, rising investments in gut health research, expansion of personalized nutrition platforms, growing integration of microbiome diagnostics, increasing focus on preventive healthcare solutions. Major trends in the forecast period include increasing adoption of probiotic and prebiotic products, rising focus on personalized nutrition solutions, growing research in microbiome-based therapies, expansion of functional and fermented food consumption, enhanced use of gut health diagnostic tools.
The growing demand for personalized medicine is expected to drive the growth of the gut microbiota market in the coming years. Personalized medicine focuses on customizing treatments for individual patients based on their genetic makeup, environmental exposure, and lifestyle factors to enhance outcomes and quality of care. Demand for personalized medicine is increasing as advances in genomics and biotechnology enable more accurate identification of individual biological profiles, supporting the development of targeted therapies that improve effectiveness and minimize side effects. In the context of gut microbiota, personalized medicine enables tailored interventions based on an individual’s unique microbiome composition, helping optimize gut health and improve outcomes in digestive and metabolic disorders. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the US Food and Drug Administration approved 26 new personalized medicines in 2023, a notable increase compared to 12 approvals in 2022. Therefore, the rising demand for personalized medicine is fueling the growth of the gut microbiota market.
Major companies operating in the gut microbiota market are concentrating on the development of innovative solutions, such as orally administered fecal microbiota therapies, to treat a range of gastrointestinal diseases and disorders. Orally administered fecal microbiota involves the use of capsules containing beneficial bacteria derived from the stool of healthy donors to help restore balance within the gut microbiome. For instance, in April 2023, Seres Therapeutics Inc., a US-based microbiome therapeutics company, received approval from the US Food and Drug Administration for Vowst, the first oral fecal microbiota product approved to prevent recurrent Clostridioides difficile (C. difficile) infection in adults aged 18 and older. Vowst is intended for use following antibacterial treatment for recurrent CDI. This approval represents a major advancement in CDI management by offering a more convenient and patient-friendly alternative to traditional fecal microbiota transplants, which are typically delivered via colonoscopy or enema. Its oral formulation may enhance patient adherence and support broader adoption of microbiome-based therapies.
In April 2023, Archer-Daniels-Midland Company (ADM), a US-based food processing company, partnered with Brightseed to develop science-backed synbiotic products designed to support gut microbiome health. This collaboration utilizes Brightseed’s artificial intelligence-driven molecular discovery platform to create evidence-based formulations aimed at improving immune function, metabolic health, and mental well-being. By combining ADM’s nutritional expertise with Brightseed’s AI-powered insights, the partnership seeks to advance next-generation gut health solutions grounded in cutting-edge scientific research. Brightseed is a US-based biotechnology company specializing in gut microbiome research through its proprietary AI platform.
Major companies operating in the gut microbiota market are Danone S.A., DuPont de Nemours Inc., International Flavors & Fragrances Inc., Seres Therapeutics, Yakult Honsha Co. Ltd., Chr. Hansen Holding A/S, Lallemand Inc., Lifeway Foods Inc., BioGaia AB, Probi AB, Seed Health, Enterome, Vedanta Biosciences Inc., Evolve BioSystems Inc., Winclove Probiotics B.V., Kallyope Inc., Sun Genomics Inc., Synlogic Inc., OpenBiome, Codex Labs Corp.
North America was the largest region in the gut microbiota market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gut microbiota market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gut microbiota market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the gut microbiota market by increasing costs of imported probiotic strains, fermentation equipment, encapsulation technologies, and diagnostic kits. Nutraceutical and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imports, while Asia-Pacific faces cost pressure on export-oriented probiotic production. These tariffs are raising product development costs and retail prices. However, they are also encouraging local strain development, domestic fermentation capacity expansion, and regional innovation in microbiome-based solutions.
The gut microbiota market research report is one of a series of new reports that provides gut microbiota market statistics, including gut microbiota industry global market size, regional shares, competitors with a gut microbiota market share, detailed gut microbiota market segments, market trends and opportunities, and any further data you may need to thrive in the gut microbiota industry. This gut microbiota market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gut microbiota refers to the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit the gastrointestinal tract. These microorganisms play a crucial role in digestion, immune system regulation, and overall health by affecting metabolism and defending the body against harmful pathogens.
The main product types in the gut microbiota market include prebiotics, probiotics, drugs, supplements, and other products. Prebiotics are non-digestible food ingredients, mainly dietary fibers, that act as a food source for beneficial gut bacteria. These products are distributed through various channels such as pharmacies and drugstores, online retail platforms, health food stores, supermarkets and hypermarkets, and specialty stores. They are used for multiple applications, including digestive health, immune health, weight management, mental health, and cardiovascular health, and are designed for different end users, including adults, children, and the elderly.
The gut microbiota market consists of sales of postbiotics, personalized nutrition products, and fecal microbiota transplantation (FMT) preparations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The gut microbiota market size is expected to see rapid growth in the next few years. It will grow to $1.47 billion in 2030 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to increasing development of microbiome-targeted therapeutics, rising investments in gut health research, expansion of personalized nutrition platforms, growing integration of microbiome diagnostics, increasing focus on preventive healthcare solutions. Major trends in the forecast period include increasing adoption of probiotic and prebiotic products, rising focus on personalized nutrition solutions, growing research in microbiome-based therapies, expansion of functional and fermented food consumption, enhanced use of gut health diagnostic tools.
The growing demand for personalized medicine is expected to drive the growth of the gut microbiota market in the coming years. Personalized medicine focuses on customizing treatments for individual patients based on their genetic makeup, environmental exposure, and lifestyle factors to enhance outcomes and quality of care. Demand for personalized medicine is increasing as advances in genomics and biotechnology enable more accurate identification of individual biological profiles, supporting the development of targeted therapies that improve effectiveness and minimize side effects. In the context of gut microbiota, personalized medicine enables tailored interventions based on an individual’s unique microbiome composition, helping optimize gut health and improve outcomes in digestive and metabolic disorders. For example, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the US Food and Drug Administration approved 26 new personalized medicines in 2023, a notable increase compared to 12 approvals in 2022. Therefore, the rising demand for personalized medicine is fueling the growth of the gut microbiota market.
Major companies operating in the gut microbiota market are concentrating on the development of innovative solutions, such as orally administered fecal microbiota therapies, to treat a range of gastrointestinal diseases and disorders. Orally administered fecal microbiota involves the use of capsules containing beneficial bacteria derived from the stool of healthy donors to help restore balance within the gut microbiome. For instance, in April 2023, Seres Therapeutics Inc., a US-based microbiome therapeutics company, received approval from the US Food and Drug Administration for Vowst, the first oral fecal microbiota product approved to prevent recurrent Clostridioides difficile (C. difficile) infection in adults aged 18 and older. Vowst is intended for use following antibacterial treatment for recurrent CDI. This approval represents a major advancement in CDI management by offering a more convenient and patient-friendly alternative to traditional fecal microbiota transplants, which are typically delivered via colonoscopy or enema. Its oral formulation may enhance patient adherence and support broader adoption of microbiome-based therapies.
In April 2023, Archer-Daniels-Midland Company (ADM), a US-based food processing company, partnered with Brightseed to develop science-backed synbiotic products designed to support gut microbiome health. This collaboration utilizes Brightseed’s artificial intelligence-driven molecular discovery platform to create evidence-based formulations aimed at improving immune function, metabolic health, and mental well-being. By combining ADM’s nutritional expertise with Brightseed’s AI-powered insights, the partnership seeks to advance next-generation gut health solutions grounded in cutting-edge scientific research. Brightseed is a US-based biotechnology company specializing in gut microbiome research through its proprietary AI platform.
Major companies operating in the gut microbiota market are Danone S.A., DuPont de Nemours Inc., International Flavors & Fragrances Inc., Seres Therapeutics, Yakult Honsha Co. Ltd., Chr. Hansen Holding A/S, Lallemand Inc., Lifeway Foods Inc., BioGaia AB, Probi AB, Seed Health, Enterome, Vedanta Biosciences Inc., Evolve BioSystems Inc., Winclove Probiotics B.V., Kallyope Inc., Sun Genomics Inc., Synlogic Inc., OpenBiome, Codex Labs Corp.
North America was the largest region in the gut microbiota market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gut microbiota market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gut microbiota market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the gut microbiota market by increasing costs of imported probiotic strains, fermentation equipment, encapsulation technologies, and diagnostic kits. Nutraceutical and pharmaceutical manufacturers in North America and Europe are most affected due to reliance on specialized imports, while Asia-Pacific faces cost pressure on export-oriented probiotic production. These tariffs are raising product development costs and retail prices. However, they are also encouraging local strain development, domestic fermentation capacity expansion, and regional innovation in microbiome-based solutions.
The gut microbiota market research report is one of a series of new reports that provides gut microbiota market statistics, including gut microbiota industry global market size, regional shares, competitors with a gut microbiota market share, detailed gut microbiota market segments, market trends and opportunities, and any further data you may need to thrive in the gut microbiota industry. This gut microbiota market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Gut microbiota refers to the diverse community of microorganisms, including bacteria, viruses, fungi, and other microbes, that inhabit the gastrointestinal tract. These microorganisms play a crucial role in digestion, immune system regulation, and overall health by affecting metabolism and defending the body against harmful pathogens.
The main product types in the gut microbiota market include prebiotics, probiotics, drugs, supplements, and other products. Prebiotics are non-digestible food ingredients, mainly dietary fibers, that act as a food source for beneficial gut bacteria. These products are distributed through various channels such as pharmacies and drugstores, online retail platforms, health food stores, supermarkets and hypermarkets, and specialty stores. They are used for multiple applications, including digestive health, immune health, weight management, mental health, and cardiovascular health, and are designed for different end users, including adults, children, and the elderly.
The gut microbiota market consists of sales of postbiotics, personalized nutrition products, and fecal microbiota transplantation (FMT) preparations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Gut Microbiota Market Characteristics
3. Gut Microbiota Market Supply Chain Analysis
4. Global Gut Microbiota Market Trends and Strategies
5. Gut Microbiota Market Analysis of End Use Industries
7. Global Gut Microbiota Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Gut Microbiota Total Addressable Market (TAM) Analysis for the Market
9. Gut Microbiota Market Segmentation
10. Gut Microbiota Market Regional and Country Analysis
11. Asia-Pacific Gut Microbiota Market
12. China Gut Microbiota Market
13. India Gut Microbiota Market
14. Japan Gut Microbiota Market
15. Australia Gut Microbiota Market
16. Indonesia Gut Microbiota Market
17. South Korea Gut Microbiota Market
18. Taiwan Gut Microbiota Market
19. South East Asia Gut Microbiota Market
20. Western Europe Gut Microbiota Market
21. UK Gut Microbiota Market
22. Germany Gut Microbiota Market
23. France Gut Microbiota Market
24. Italy Gut Microbiota Market
25. Spain Gut Microbiota Market
26. Eastern Europe Gut Microbiota Market
27. Russia Gut Microbiota Market
28. North America Gut Microbiota Market
29. USA Gut Microbiota Market
30. Canada Gut Microbiota Market
31. South America Gut Microbiota Market
32. Brazil Gut Microbiota Market
33. Middle East Gut Microbiota Market
34. Africa Gut Microbiota Market
36. Gut Microbiota Market Competitive Landscape and Company Profiles
37. Gut Microbiota Market Other Major and Innovative Companies
40. Gut Microbiota Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Gut Microbiota Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses gut microbiota market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gut microbiota? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gut microbiota market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Prebiotics; Probiotics; Drugs; Supplements; Other Products2) By Application: Digestive Health; Immune Health; Weight Management; Mental Health; Cardiovascular Health
3) By Distribution Channel: Pharmacies And Drugstores; Online Retail; Health Food Stores; Supermarkets And Hypermarkets; Specialty Stores
4) By End-Users: Adults; Children; Elderly
Subsegments:
1) By Prebiotics: Fructooligosaccharides (Fos); Galactooligosaccharides (Gos); Inulin; Resistant Starch; Beta-Glucans; Arabinogalactans; Pectins2) By Probiotics: Lactobacillus; Bifidobacterium; Saccharomyces; Streptococcus; Bacillus; Escherichia
3) By Drugs: Antibiotics; Bacteriophage Therapy; Gut Microbiota Modulators; Immunomodulators; Antidiarrheal Agents; Laxatives
4) By Supplements: Synbiotics; Postbiotics; Enzyme Supplements; Vitamin D Supplements; Omega-3 Fatty Acids; Herbal Extracts
5) By Other Products: Functional Foods; Fermented Foods; Beverages; Gut Health Diagnostic Kits; Dietary Fiber Products
Companies Mentioned: Danone S.A.; DuPont de Nemours Inc.; International Flavors & Fragrances Inc.; Seres Therapeutics; Yakult Honsha Co. Ltd.; Chr. Hansen Holding A/S; Lallemand Inc.; Lifeway Foods Inc.; BioGaia AB; Probi AB; Seed Health; Enterome; Vedanta Biosciences Inc.; Evolve BioSystems Inc.; Winclove Probiotics B.V.; Kallyope Inc.; Sun Genomics Inc.; Synlogic Inc.; OpenBiome; Codex Labs Corp.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Gut Microbiota market report include:- Danone S.A.
- DuPont de Nemours Inc.
- International Flavors & Fragrances Inc.
- Seres Therapeutics
- Yakult Honsha Co. Ltd.
- Chr. Hansen Holding A/S
- Lallemand Inc.
- Lifeway Foods Inc.
- BioGaia AB
- Probi AB
- Seed Health
- Enterome
- Vedanta Biosciences Inc.
- Evolve BioSystems Inc.
- Winclove Probiotics B.V.
- Kallyope Inc.
- Sun Genomics Inc.
- Synlogic Inc.
- OpenBiome
- Codex Labs Corp.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.77 Billion |
| Forecasted Market Value ( USD | $ 1.47 Billion |
| Compound Annual Growth Rate | 17.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
